Virtus ETF Advisers LLC Sells 1,904 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Virtus ETF Advisers LLC trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS) by 40.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,834 shares of the company’s stock after selling 1,904 shares during the quarter. Virtus ETF Advisers LLC’s holdings in NewAmsterdam Pharma were worth $73,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of NewAmsterdam Pharma by 168.7% in the 3rd quarter. State Street Corp now owns 37,915 shares of the company’s stock valued at $629,000 after purchasing an additional 23,805 shares in the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares in the last quarter. Geode Capital Management LLC boosted its stake in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares in the last quarter. JPMorgan Chase & Co. grew its position in NewAmsterdam Pharma by 176.9% in the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after acquiring an additional 14,280 shares during the last quarter. Finally, HB Wealth Management LLC acquired a new position in NewAmsterdam Pharma during the fourth quarter worth about $224,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director James N. Topper acquired 1,135 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. This represents a 0.04 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Stock Up 1.8 %

NASDAQ NAMS opened at $17.83 on Tuesday. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -6.86 and a beta of -0.01. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The stock has a fifty day simple moving average of $19.58 and a 200 day simple moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. Research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Buy” and an average target price of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.